07.08.26 -- Rethinking Biotech Growth: Is More Capital the Answer?

What is critical when choosing a CDMO as a partner for HPAPI development and manufacturing? Brian Haney breaks down the key questions, controls, and expertise every innovator should evaluate.

Develop optimized lipid-based formulations to overcome solubility, stability, and food-effect challenges, enabling high-dose oral delivery and rapid progression to Phase 1 trials.

Sterile drug production relies on multi-stage filtration to reduce microbial load and prevent filter fouling. This strategy ensures consistent product quality, process efficiency, and patient safety.

Learn how leveraging a customs warehouse can streamline your supply chain, reduce VAT costs, and enhance global compliance and efficiency.

The development of physically stable, biologically active dry powder formulations of large molecules for inhalation has remained a challenge.

In the face of increasing molecular complexity, early developability assessment with a skilled CDMO can reduce pharmaceutical development costs, prevent clinical delays, and improve commercial success.

Strategic tech transfer and scalable manufacturing enabled rapid NDA approval, delivering registration batches and accelerating commercialization of a novel therapy for drug-resistant infections.